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William A. Zoghbi, MD,* Jagat Narula, MD, PHDyI schemic heart disease with resultant left ventric-ular (LV) dysfunction is the major underlyingcause of heart failure and carries signiﬁcant
morbidity and mortality. Therapeutic endeavors to
improve the prognosis of these patients have evolved
over the years and include a multifaceted approach
aimed at alleviating symptoms and improving ventric-
ular function, and reducing reinfarction and sudden
death, using multidrug therapy, revascularization
procedures, implantable cardioverter-deﬁbrillators
and resynchronization devices. Over the past 40
years, with the introduction of the concept of myocar-
dial viability and reversibility of LV function with
revascularization and medical therapy, numerous in-
vestigations have attempted to identify how best to
detect viability, particularly with various imaging
modalities, and identify the most suitable candidates
for revascularization with the aim to reverse remodel-
ing, enhance ventricular function, and improve over-
all prognosis.
Prior to the STICH (Surgical Treatment for Ischemic
Heart Failure) trial (1,2), numerous tacitly proved
notions were widely believed:
1. Myocardial viability is better assessed by imaging
techniques, with higher sensitivity with nuclear
modalities, higher speciﬁcity with wall motion
techniques, and cardiac magnetic resonance pro-
viding unique visualization of myocardial scar.
2. The mechanism of viability, ventricular remod-
eling, and reverse remodeling in ischemic LV
dysfunction is complex at all vascular, myocardial,
and molecular levels.From the *Cardiovascular Imaging Institute, Houston Methodist DeBakey
Heart and Vascular Center, Houston, Texas; and the yIcahn School of
Medicine at Mount Sinai, New York, New York. The authors have
reported that they have no relationships relevant to the contents of
this paper to disclose.3. The presence of ischemia, resting and inducible,
is the most predictive of recovery of function.
4. The larger the amount of viability, the larger
the improvement in ventricular function after
revascularization.
5. Patients with viability who undergo revasculari-
zation have a better prognosis than those treated
medically or who have no viability.
6. There may be an extent of ventricular remodeling
beyond which the beneﬁts of revascularization are
no longer seen despite the presence of viability.
Most of the underlying clinical investigations
behind these themes, although well conducted, had
some methodological issues; either they were retro-
spective, without control subjects, or they were not
randomized, particularly when addressing the out-
comes of a treatment approach (e.g., medical therapy
vs. revascularization). Despite these limitations,
there was general consensus that viability was
important and provided an additional parameter for
improving ventricular function and prognosis after
revascularization, beyond medical therapy.
The STICH trial was a prospective, randomized
trial evaluating whether coronary artery bypass graft
(CABG) surgery is superior to optimal medical therapy
(OMT) in patients with severely depressed LV func-
tion, amenable to revascularization (1). However, it
was not designed to address the issue of myocardial
viability in ischemic LV dysfunction, as viability
testing was not mandated, and patients were not
randomized on the basis of testing results. Yet its
substudy on viability (2) called into question some
of the generally accepted themes in myocardial
viability, particularly relating to revascularization
and prognosis. Has the current therapeutic era
changed this paradigm, given that medical therapy,
implantable cardioverter-deﬁbrillators, and nonsur-
gical revascularization procedures have substantially
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1236evolved in the interim? Is viability testing still
important in the setting of ischemic LV dysfunction?
Are outcomes with OMT similar to those with CABG
in such patients and does the amount of viability
modulate prognosis? And last, is viability in the
patient with extreme remodeling irrelevant?
In this issue of iJACC, Bonow et al. (3) address
the latter of these questions from the extension of
the substudy on viability of STICH (2), and their
study is accompanied by a thoughtful editorial by Dr.
Konstam (4). In this large cohort, patients with more
advanced ventricular remodeling and no viability had
the worst prognosis, a ﬁnding that is in agreement
with previous observations. However, no interaction
was noted between treatment modality (CABG vs.
OMT) and LV size or degree of viability.
Previous studies on the role of the degree of LV
remodeling and viability are scarce (5–7). Numbers of
patients were small, the outcome assessed was usu-
ally change in LV function rather than a clinical
outcome, and patients were highly selected. The
present study, in contrast, involves the large number
of well-characterized patients and addresses the
issues of remodeling, viability, and intervention. One
facet of the ﬁndings is the comparable outcomes of
revascularization and OMT in this patient popula-
tion. It is the same issue that surfaced in the previ-
ous viability substudy of STICH, and thus the results
are not completely unexpected, as they are derived
from the same data. The various reasons for such
ﬁndings have been discussed extensively by the
investigators and in previous debates (8,9) and
may be related to the select population in STICH
that underwent viability testing, the high degree of
OMT achieved, the use of implantable cardioverter-
deﬁbrillators, and the characteristics of the overall
population in STICH (including less severe angina,
higher prevalence of single-vessel disease, difﬁcult
patient enrollment in the study and thus a more
select cohort, fewer comorbidities, the requirement
for coronary anatomy amenable to revascularization
and the more severe LV function at entry).
Do LV size and viability matter? Indeed, both LV
size and viability matter. The present study and
earlier ones have shown worse outcomes in patients
with more reduced LV function, excessively enlarged
ventricles, and no viability. The major question to be
answered is whether there is a threshold of LV size or
viability extent beyond which the relative beneﬁts of
revascularization in relation to OMT are modiﬁed.
The present investigation, although not designed to
address this question prospectively and in a ran-
domized fashion, gives the most robust data so far.
However, it is not a deﬁnite answer. Patients in thissubstudy had a wide range of LV sizes within the
select clinical characteristics of STICH, and there was
no interaction between LV size and mode of therapy.
However, the same cannot be said conclusively about
viability, as the vast majority of patients in this
substudy had viability (81%), and the pre-speciﬁed
viability cutoff deﬁnition in STICH is quite high ($11
of 17 segments by nuclear imaging, $5 of 16 segments
by dobutamine echocardiography), increasing even
further the prevalence and speciﬁcity of viability in
the population studied. Thus the prognostic impact of
a true lack of viability (or a smaller extent) and
its interaction with LV remodeling and treatment
modality cannot be fully assessed. Of interest, there
was a trend toward better outcomes in patients with
less viability and larger ventricles who underwent
CABG compared with OMT; the number of patients in
this category, however, was small (3).
Patients with ischemic LV dysfunction face a sig-
niﬁcant challenge. Although the present study cannot
fully address the issue of the signiﬁcance of viability
in its total spectrum, it adds important data to our
knowledge in patients with ischemic LV dysfunction.
Patients with moderate or large extent of viability
who have clinical characteristics similar to those in
STICH appear to fare equally well in the long term
with CABG and OMT, and there is no threshold effect
of LV volumes within this range of viability, welcome
news for patients. Ideally, one would like to see
the clinical importance of viability tested in its full
spectrum, prospectively, in a randomized design,
using uniform imaging methodology, inclusive of
magnetic resonance. However, this has proved to be a
daunting task from past experience, partly because of
entrenched clinical practices. In the interim, de-
cisions on the management of individual patients
with coronary artery disease and LV dysfunction will
always have to take into consideration a multitude of
factors, including symptoms and severity of angina
and/or heart failure, degree of LV dysfunction, coro-
nary anatomy, correlation of coronary disease to
regional dysfunction and viability, the presence and
extent of ischemia, comorbidities inclusive of age,
feasibility and type of revascularization, and patient
preference. As medical options and revascularization
procedures continue to evolve and improve, the
complexity of such management decisions is palpable
and thus mandates that cardiologists, surgeons, and
patients navigate this wide array of options together.
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